# A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions

> **NCT04477850** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 30 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Luspatercept

## Key facts

- **NCT ID:** NCT04477850
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-30
- **Primary completion:** 2023-09-29
- **Final completion:** 2026-04-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04477850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04477850, "A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04477850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*